Вивчення нефропротекторної ефективності ірбесартану у хворих із діабетичною нефропатією

О. С. Ларін, К. О. Зуєв, В. І. Паньків, Т. Ю. Юзвенко, Г. А. Кидалова, Д. Г. Когут, Т. І. Дашук

Повний текст:

PDF

Посилання


Zimmet P., Alberti K.G., Shaw J. Global and societal implications of the diabetes epidemic // Nature. – 2001. – Vol. 414 – P. 782-787. https://doi.org/10.1038/414782a

Raptis A.E., Viberti G. Pathogenesis of diabetic nephropathy // Exp. Clin. Endocrinol. Diabetes. – 2001. – Vol. 109(2). – P. 424-437. https://doi.org/10.1055/s-2001-18600

Castellino P., Shohat J., DeFronzo R.A. Hyperfiltration and diabetic nephropathy: is it the beginning? Or is it the end? // Semin. Nephrol. – 1990. – Vol. 10(3). – P. 228-241.

Yilmaz M.I., Saglam M., Qureshi A.R. et al. Endothelial dysfunction in type-2 diabetics with early diabetic nephropathy is associated with low circulating adiponectin // Nephrol. Dial. Transplant. – 2008. – Vol. 23(5). – P. 1621-1627. https://doi.org/10.1093/ndt/gfm828

Seo J.Y., Park J., Yu M.R. et al. Positive feedback loop between plasminogen activator inhibitor-1 and transforming growth factor-beta1 during renal fibrosis in diabetes // Am. J. Nephrol. – 2009. – Vol. 30(6). – P. 481-490. https://doi.org/10.1159/000242477

Taslipinar A., Yaman H., Yilmaz M.I. et al. The relationship between inflammation, endothelial dysfunction and proteinuria in patients with diabetic nephropathy // Scand. J. Clin. Lab. Invest. – 2011. – Vol. 71(7). – P. 606-612. https://doi.org/10.3109/00365513.2011.598944

Dengel D.R., Glodberg A.P., Mayuga R.S. et al. Insulin resistance, elevated glomerular filtration fraction and renal injury // Hypertension. – 1996. – Vol. 28. – P. 127-132. https://doi.org/10.1161/01.hyp.28.1.127

Шестакова М. В., Кутырина И. В., Рагозин А. К. Роль сосудистого эндотелия в регуляции почечной гемодинамики // Тер. архив. – 1994. – 12. – С. 83-86.

Шестакова М. В., Неверов Н. И., Дедов И. В. Роль внутриклубочковой гипертензии и липидов в развитии диабетической нефропатии // Тер. архив. – 1993. – 16. – С. 61-65.

Mogensen C.E., Chachati A., Christensen C.K. et al. Microalbuminuria: An early marker of renal involvement in diabetes // Uremia Invest. – 1985. – Vol. 9. – P. 85-95. https://doi.org/10.3109/08860228509088195

Caramori M.L., Fioretto P., Mauer M. The need for early predictors of diabetic nephropathy risk: Is albumin excretion rate sufficient? // Diabetes. – 2000. – Vol. 49. – P. 1399-1408. https://doi.org/10.2337/diabetes.49.9.1399

Poggio E.D., Wang X., Greene T., Van Lente F., Hall P.M. Performance of the Modification of Diet in Renal Disease and Cockcroft-Gault equations in the estimation of GFR in health and in chronic kidney disease // J. Am. Soc. Nephrol. – 2005. – Vol. 16. – P. 459-466. https://doi.org/10.1681/asn.2004060447

Bosch J.P., Lauer A., Glabman S. Short-term protein loading in assessment of patients with renal disease // Am. J. Med. – 1984. – Vol. 77. – P. 873-879. https://doi.org/10.1016/0002-9343(84)90529-1

Bosch J.P., Lew S., Glabman S., Lauer A. Renal hemodynamic changes in humans: response to protein loading in normal and diseased kidneys / / Am. J. Med. – 1986. – Vol. 81. – P. 809-816. https://doi.org/10.1016/0002-9343(86)90350-5

Amiel C., Blanchet F., Friedlander G. et al. Renal functional reserve // Nephrol. Dial. Transplant. 1990. – Vol. 5. – P. 763-770. https://doi.org/10.1093/ndt/5.9.763

Хіміч А. В., Романів Л. В. До методики вивчення функціонального ниркового резерву у людини // Здобутки клінічної і експериментальної медицини. – 2008. – 12(9). – C. 153.

Арьев А. Л. Возможности использования субмаксимального нагрузочного теста для оценки функционального состояния почек в практике ВТЭ // Организационно-методические вопросы социально-трудовой реабилитации инвалидов. Сб. науч. тр. - Л. - 1987. – C. 45-50.

Гоженко А. И., Куксань Н. И., Гоженко Е. А. Методика определения почечного фукционального резерва у человека // Нефрология. – 2001. – 14. – С. 70-73.

Шестакова М. В., Дедов И. И., Мухин Н. А. и соавт. Восстановление резерва фильтрационной функции почек у больных сахарным диабетом при лечении каптоприлом // Тер. архив. – 1991. – 16. – C. 50-55.

Паливода С. Н., Черепок А. А., Кулинич Р. Л. Оценка функционального состояния почек как предиктора эффективности антигипертензивной терапии у больных с гипертонической болезнью // Укр. кардіол. журн. – 2005. – 13. – С. 90-95.

Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation. Geneva, World Health Org. – 2006. – 46 p.

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease // Am. J. Kidney Dis. – 2007. – Vol. 49(2). – P. S1-S180. https://doi.org/10.1053/j.ajkd.2006.12.005

Лакин Г. Ф. Биометрия. М.: Высшая школа. – 1990. – 352 с.

Parving H.H., Lehnert H., Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes // N. Engl. J. Med. – 2001. – Vol. 345. – P. 870-878. https://doi.org/10.1056/nejmoa011489

Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. – 2001. – Vol. 345. – P. 851-860. https://doi.org/10.1056/nejmoa011303

Giorgino F., Laviola L., Cavallo Perin P. et al. Factors associated with progression to macroalbuminuria in microalbuminuric type 1 diabetic patients: The EURODIAB Prospective Complications Study // Diabetologia. – 2004. – Vol. 47. – P. 1020-1028. https://doi.org/10.1007/s00125-004-1413-8

Hovind P., Tarnow L., Parving H.H. Remission and regression of diabetic nephropathy // Curr. Hypertens. Rep. – 2004. – Vol. 6. – P. 377-382. https://doi.org/10.1007/s11906-004-0057-x

Chan A.Y.M., Cheng M.L.L., Keil L.C., Myers B.D. Functional response of healthy and diseased glomeruli to a large, protein-rich meal // J. Clin. Invest. – 1988. – Vol. 81. – P. 245-254. https://doi.org/10.1172/jci113302

Schupp M., Janke J., Clasen R. et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity // Circulation. – 2004. – Vol. 109. – P. 2054-2057. https://doi.org/10.1161/01.cir.0000127955.36250.65

Rangwala S.M., Lazar M.A. Peroxisome proliferator-activated receptor gamma in diabetes and metabolism // Trends Pharmacol. Sci. – 2004. – Vol. 25(6). – P. 331-336. https://doi.org/10.1016/s0165-6147(04)00115-4

Takano H., Komuro I. Roles of peroxisome proliferator-activated receptor gamma in cardiovascular disease // J. Diabetes Complicat. – 2002. – Vol. 16(1). – P. 108-114. https://doi.org/10.1016/s1056-8727(01)00203-3

Parhofer K.G., Muenzel F., Krekler M. Effect of the Angiotensin Receptor Blocker Irbesartan on Metabolic Parameters in Clinical Practice: the DO-IT Prospective Observational Study // Cardiovasc. Diabetol. – 2007. – Vol. 6(1). – P. 36. https://doi.org/10.1186/1475-2840-6-36

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report // Circulation. – 2002. – Vol. 106(25). – P. 3143-3421.

Kintscher U., Bramlage P., Paar W.D. et al. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14 200 patients // Cardiovasc. Diabetol. – 2007. – Vol. 6. – P. 12. https://doi.org/10.1186/1475-2840-6-12

Isomaa B., Almgren P., Tuomi T. et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome // Diabetes Care. – 2001. – Vol. 24. – P. 683-689. https://doi.org/10.2337/diacare.24.4.683

Grundy S.M., Cleeman J.I., Merz C.N. et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines // Circulation. – 2004. – Vol. 110. – P. 227-239. https://doi.org/10.1161/01.cir.0000133317.49796.0e

Schmieder R.E., Veelken R., Gatzka C.D. et al. Predictors for hypertensive nephropathy: results of a 6-year follow-up study in essential hypertension // J. Hypertens. – 1995. – Vol. 13(3). – P. 357-365. https://doi.org/10.1097/00004872-199503000-00012

Nakano S., Fukuda M., Hotta F. et al. Reversed Circadian Blood Pressure Rhythm Is Associated With Occurrences of Both Fatal and Nonfatal Vascular Events in NIDDM Subjects // Diabetes. – 1998. – Vol. 47. – P. 1501-1506. https://doi.org/10.2337/diabetes.47.9.1501

Nakano S., Ogihara M., Tamura C. et al. Reversed Circadian Blood Pressure Rhythm Independently Predicts Endstage Renal Failure in Non-Insulin-Dependent Diabetes Mellitus Subjects // Journal of Diabetes and Its Complications. – 1999. – Vol. 13. – P. 224-231. https://doi.org/10.1016/s1056-8727(99)00049-5

Inaba M., Negishi K., Takahashi M., et al. Increased night:day blood pressure ratio in microalbuminuric normotensive NIDDM subjects // Diabetes Res. Clin. Pract. – 1998. – Vol. 40(3). – P. 161-166. https://doi.org/10.1016/s0168-8227(98)00026-6

Staessen J.A., Fagard R., Thijs L. et al. for the Systolic Hypertension in Europe (Syst-Eur) Trial investigators. Randomised double-blind comparison of placebo and active treatment or older patients with isolated systolic hypertension // Lancet. – 1997. – Vol. 350. – P. 757-764. https://doi.org/10.1016/s0140-6736(97)05381-6

Czupryniak L., Wisniewska-Jaronsinska M., Drzewoski J. Trandolapril restores circadian blood pressure variation in normoalbuminuric normotensive Type 1 diabetic patients // J. Diabetes Complications. – 2001. – Vol. 15(2). – P. 75-79. https://doi.org/10.1016/s1056-8727(00)00130-6


Пристатейна бібліографія ГОСТ






DOI: https://doi.org/10.24026/1818-1384.1(38).2012.81060



Creative Commons License
Ця робота ліцензована Creative Commons Attribution-NonCommercial 4.0 International License.

© Клінічна ендокринологія та ендокринна хірургія.

ISSN: 1818-1384 (Print), e-ISSN: 2519-2582, DOI: 10.24026/1818-1384.

При копіюванні активне посилання на матеріал обов'язкове.

Flag Counter